Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.52 |
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.50 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.49 |
| ▸ | GRPR | P30550 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265201 | 0.96 | PRMT1 (0.53) | CCKBRRXFP1MAGI3PRMT1IL23R | |
| SCHEMBL30342394 | 0.94 | MAGI3 (0.54) | CCKBRRXFP1MAGI3PRMT1IL23R | |
| SCHEMBL31018602 | 0.93 | MAGI3 (0.56) | CCKBRRXFP1MAGI3PRMT1IL23R | |
| SCHEMBL29939669 | 0.87 | PRMT1 (0.58) | CCKBRMAGI3PRMT1IL23RGRPR | |
| SCHEMBL29742991 | 0.85 | EDNRA (0.54) | RXFP1MAGI3PRMT1GRPRGLP1R | |
| SCHEMBL30692610 | 0.84 | IL23R (0.59) | CCKBRIL23RGRPR | |
| SCHEMBL30082892 | 0.84 | CCKBR (0.59) | CCKBRIL23RGLP1R | |
| SCHEMBL31182529 | 0.84 | MAGI3 (0.59) | RXFP1MAGI3IL23RGRPRGLP1R | |
| SCHEMBL38663457 | 0.84 | KEAP1 (0.57) | CCKBRRXFP1IL23RGRPRGLP1R | |
| SCHEMBL30903449 | 0.83 | OPRD1 (0.53) | CCKBRMAGI3PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | MAGNI GUIDO (CH) | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400638-A1 | COMBINATION OF RELAXIN AND VASOPRESSIN ANALOGUES FOR TREATMENT OF RENAL DISORDERS OR CONDITIONS | AVPR2, RXFP1, RXFP2 | CCKBR 125/4885RXFP1 2/4885MAGI3 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.